# Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)

> **NCT01253408** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 36 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Dronabinol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01253408
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-05-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01253408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01253408, "Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01253408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*